JPRN-UMIN000034454已完成1 期
A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeated doses of ART-648/TAK-648 in healthy Japanese volunteers - Phase 1 study of ART-648/TAK-648
Dept of Clinical Pharmacology and Therapeutics, Oita University Faculty of Medicine0 个研究点目标入组 44 人开始时间: 2018年11月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 45years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Have a significant complication which may affect drug evaluation, such as digestive, liver, musculoskeletal, respiratory, brain, cardiovascular, blood, tumor, endocrine, immune, nervous, psychiatric, urogenital diseases 2. Subjects who have complications or history of kidney disease 3. Subjects who have complications or history of liver disease 4. Subjects who have a history of surgical operations or medical disorders judged by the investigator that may affect the absorption, distribution, metabolism, excretion of the drug 5. Subjects who used drugs or herbal medicine products within 2 weeks before the investigational drug administration or who may need such drugs 6. Subjects who ingested grapefruit, oranges or apples and juice or foods containing them within 72 hours before the investigational drug administration 7. Subjects who took alcohol exceeding 10 units per week 8. Subjects who habitually ingest coffee, tea, green tea, cola, other caffeinated beverages exceeding 6 cups per day 9. Smokers or subjects who smoked or used nicotine containing products within 6 months before the screening test 10. Subjects who collected 400 mL or more of blood within 12 weeks or collected 200 mL of blood within 4 weeks or donated blood component within 2 weeks before the study drug administration, or subjects who collected more than 1200 mL of blood per year 11. Participation in a clinical trial of an investigational drug within 4 months or of an approved drug within 3 months before the first drug administration 12. Have surgical operations for 4 weeks before screening tests 13. Subjects with a history of severe or multiple allergies, or with a history of hypersensitivity reaction to drugs 14. Have a history of drug or alcohol abuse 15. Subjects with significant electrocardiogram abnormalities, including QTcF> 450 msec in screening tests 16. Positive for immunological test 17. Women who are or may be pregnant, who are lactating
研究者
相似试验
已完成
1 期
ART-001 Phase 1 studyHealthy volunteersJPRN-jRCT2080225277ARTham Therapeutics Inc.32
已完成
不适用
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of OMS1029 with single-dose intravenous and subcutaneous administration in healthy subjectsNL-OMON53550Omeros Corporation48
已完成
不适用
GEN-001 single dose phase 1 studyKCT0005339Chonbuk National University Hospital20
已完成
1 期
Inhalation of Leukotriene B4 (LTB4) in patients suffering from BronchiectasisBronchiectasisACTRN12614001199606TB4 Sweden AB30
已完成
1 期
Phase I trial to evaluate the safety and tolerability of GDC-0214 in healthy volunteers and patients with mild asthmaAsthmaRespiratory - AsthmaACTRN12617001227381Genentech, Inc.102